<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Hangzhou Diagens Biotechnology Co., Ltd. Class H — News on 6ix</title>
<link>https://6ix.com/company/hangzhou-diagens-biotechnology-co-ltd-class-h</link>
<description>Latest news and press releases for Hangzhou Diagens Biotechnology Co., Ltd. Class H on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 30 Apr 2026 05:18:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/hangzhou-diagens-biotechnology-co-ltd-class-h" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d5d7d4beedb30cb6fa45b5.webp</url>
<title>Hangzhou Diagens Biotechnology Co., Ltd. Class H</title>
<link>https://6ix.com/company/hangzhou-diagens-biotechnology-co-ltd-class-h</link>
</image>
<item>
<title>Diagens Annual Results: 100B-Parameter Model Reshapes Medical AI Landscape; Licensing Revenue Becomes Primary Growth Engine</title>
<link>https://6ix.com/company/hangzhou-diagens-biotechnology-co-ltd-class-h/news/diagens-annual-results-100b-parameter-model-reshapes-medical-ai-landscape-licensing-revenue-becomes-primary-growth-engine</link>
<guid isPermaLink="true">https://6ix.com/company/hangzhou-diagens-biotechnology-co-ltd-class-h/news/diagens-annual-results-100b-parameter-model-reshapes-medical-ai-landscape-licensing-revenue-becomes-primary-growth-engine</guid>
<pubDate>Thu, 30 Apr 2026 05:18:00 GMT</pubDate>
<description>Hangzhou Diagens Biotech Co., Ltd. (HKEX: 2526, "Diagens"), a pioneer in medical imaging foundation models, today announced its first annual results since its listing. The report marks a pivotal milestone in the company's transition from technical validation to large-scale commercialization, with annual revenue reaching RMB 164 million, a year-on-year increase of 133.7%.</description>
</item>
</channel>
</rss>